Le Lézard
Classified in: Health
Subjects: CCA, MAT

Numinus to Host Q1 Fiscal 2024 Results Conference Call on January 15, 2024


VANCOUVER, BC, Jan. 2, 2024 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioural health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, will release its financial results for the quarter ended November 30, 2023, after market close on Tuesday, January 15, 2024.

Interested parties are invited to participate in the Company's Q1 2024 results conference call and webcast occurring on the same day at 5:30 p.m. Eastern time / 2:30 p.m. Pacific time. During the call, Numinus executives will review the Company's performance and recent initiatives.

A question-and-answer session will follow management's prepared remarks. At this time, the operator will provide instructions for qualified equity analysts to submit questions. Investors are invited to submit questions by email to [email protected]. A selection of questions will be answered by management on the call, and all emailed questions will be responded to by email.

To listen to the live webcast, please register at:
https://events.q4inc.com/attendee/589132840  

The webcast will also be archived on the Events and Presentations page of Numinus' Investor Relations website: https://www.investors.numinus.com/events-and-presentations/

To participate in the live conference call, please use the following dial-in information:

To avoid any delays in joining the call, please dial in at least five minutes prior to the call start time. If prompted, please provide conference passcode 3547386.

A replay of the conference call can also be accessed after 8:30 p.m. Eastern time / 5:30 p.m. Pacific time on January 15, 2024, at 1-800-770-2030 or 1-647-362-9199 (using passcode 3547386). The replay will be available until January 29, 2024.

About Numinus

Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model ? including psychedelic research and clinic care ? is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.

Learn more at www.numinus.com and follow us on LinkedInFacebookTwitter, and Instagram.

SOURCE Numinus Wellness Inc.


These press releases may also interest you

at 02:27
Market Overview The Global Biometric Technologies Market is expected to grow at a compound annual growth rate (CAGR) of around 12% between 2024 and 2031, from an estimated USD 38 billion in 2023 to approximately USD 120 billion by 2031. Our study...

at 02:05
Locate Bio, a pioneering orthobiologics company, today announces the successful completion of an oversubscribed £9.2 million funding round from both new investors and existing investors, Mercia Ventures and BGF. The proceeds will fund a clinical...

at 02:05
Positive topline results from the DESTINY-Breast06 phase 3 trial showed that ENHERTU® (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard of...

at 01:00
April 29, 2024 First-quarter highlights Group sales amounted to EUR 4.1 billion, with comparable sales growth of 2.4%Comparable order intake -3.8%, mainly due to ChinaUSD 1.1 billion Respironics litigation settlement reached in the US...

at 00:45
4P-Pharma, a Lille-based clinical-stage startup studio focused on developing curative therapies for untreated serious diseases, announces that it has successfully secured a total capital of ?15 million in its second closing with participation from...

at 00:20
PROTEINA announced today that it has held a kickoff meeting with Professor Janghee Woo and his research team at Emory University School of Medicine in Atlanta, to begin global clinical validation of its flagship product, PPI PathFinder BCL2 Dx. PPI...



News published on and distributed by: